{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:47:41Z","timestamp":1774122461400,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,10,25]],"date-time":"2005-10-25T00:00:00Z","timestamp":1130198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s10067-005-0043-y","type":"journal-article","created":{"date-parts":[[2005,10,24]],"date-time":"2005-10-24T13:54:46Z","timestamp":1130162086000},"page":"749-752","source":"Crossref","is-referenced-by-count":39,"title":["Rasburicase treatment in severe tophaceous gout: a novel therapeutic option"],"prefix":"10.1007","volume":"25","author":[{"given":"J. D.","family":"Moolenburgh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Reinders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. L. Th. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,25]]},"reference":[{"key":"43_CR1","volume-title":"Conn's current therapy","author":"AG Fam","year":"1999","unstructured":"Fam AG (1999) Hyperuricemia and gout. In: Rakel RE (ed) Conn's current therapy, 51st edn. Saunders, Philadelphia, pp 561\u2013566","edition":"51st edn"},{"key":"43_CR2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","volume":"334","author":"BT Emmerson","year":"1996","unstructured":"Emmerson BT (1996) The management of gout. N Engl J Med 334:445\u2013451","journal-title":"N Engl J Med"},{"issue":"17","key":"43_CR","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","volume":"349","author":"RA Terkeltaub","year":"2003","unstructured":"Terkeltaub RA (2003) Gout. N Engl J Med 349(17):1647\u20131655","journal-title":"N Engl J Med"},{"issue":"8","key":"43_CR4","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","volume":"50","author":"JD Bieber","year":"2004","unstructured":"Bieber JD, Terkeltaub RA (2004) Gout; on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50(8):2400\u20132414","journal-title":"Arthritis Rheum"},{"key":"43_CR5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonzo-Ruiz A, Calabozo M et al (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545\u2013549","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"43_CR6","first-page":"651","volume":"22","author":"TLThA Jansen","year":"2004","unstructured":"Jansen TLThA, Reinders MK, Van Roon EN, Brouwers JRBJ (2004) Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d? Clin Exp Rheumatol 22(5):651","journal-title":"Clin Exp Rheumatol"},{"key":"43_CR7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/ard.2003.015743","volume":"63","author":"AK Tausche","year":"2004","unstructured":"Tausche AK, Richter K, Gr\u00e4ssler A, H\u00e4nsel S, Roch B, Schr\u00f6der HE (2004) Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63:1351\u20131352","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"43_CR8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093\u20131103","journal-title":"N Engl J Med"},{"key":"43_CR9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","volume":"116","author":"MB Davidson","year":"2004","unstructured":"Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546\u2013555","journal-title":"Am J Med"},{"issue":"5","key":"43_CR10","first-page":"392","volume":"62","author":"S Rozenberg","year":"1995","unstructured":"Rozenberg S, Roch B, Dorent R, Koeger AC, Borget Wrona N, Bourgeois P (1995) Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum (Engl Ed) 62(5):392\u2013394","journal-title":"Rev Rhum Engl Ed"},{"key":"43_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","volume":"15","author":"JN Loeb","year":"1972","unstructured":"Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15:189\u2013192","journal-title":"Arthritis Rheum"},{"key":"43_CR12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.1780080431","volume":"8","author":"JE Seegmiller","year":"1965","unstructured":"Seegmiller JE (1965) The acute attack of gouty arthritis. Arthritis Rheum 8:714\u2013723","journal-title":"Arthritis Rheum"},{"key":"43_CR13","first-page":"577","volume":"28","author":"J Li-Yu","year":"2001","unstructured":"Li-Yu J, Clayburne G, Sieck M et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577\u2013580","journal-title":"J Rheumatol"},{"key":"43_CR14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jama.1994.03510280064034","volume":"271","author":"DJ Mc Carty","year":"1994","unstructured":"Mc Carty DJ (1994) Gout without hyperuricemia. JAMA 271:302\u2013303","journal-title":"JAMA"},{"key":"43_CR15","first-page":"908","volume":"22","author":"MB Ferraz","year":"1995","unstructured":"Ferraz MB, O'Brien B (1995) A cost effective analysis of urate lowering drugs in non-tophaceous recurrent gouty arthritis. J Rheumatol 22:908\u2013914","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0043-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-005-0043-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0043-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:50:50Z","timestamp":1559105450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-005-0043-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,25]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1007\/s10067-005-0043-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,25]]}}}